Related Experiment Video

Updated: Oct 9, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.6K

Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review

F A Diepstraten1, A E Hoetink2, M van Grotel1

  • 1Princess Máxima Center for pediatric oncology, Utrecht, The Netherlands.

Jac-Antimicrobial Resistance
|December 17, 2021
PubMed

Insights

Aminoglycoside and glycopeptide ototoxicity in children varies widely, influenced by drug type and co-medications. Regular audiological exams are recommended for children on these drugs, especially with other ototoxic agents.

Area of Science:

  • Pediatric Pharmacology
  • Ototoxicology
  • Evidence-Based Medicine

Background:

  • Ototoxicity is a known adverse effect of aminoglycoside and glycopeptide antibiotics.
  • Understanding the risks in pediatric populations is crucial for safe medication use.

Purpose of the Study:

  • To systematically review the available evidence on ototoxicity caused by aminoglycosides and glycopeptides in children.
  • To identify factors influencing the occurrence and determinants of this ototoxicity.

Main Methods:

  • Conducted systematic literature searches in major databases (PubMed, EMBASE, Cochrane Library).
  • Included studies with at least 50 pediatric participants, focusing on ototoxicity and relevant antibiotic administration.
  • Assessed study quality and risk of bias using standardized tools (QUIPS, Cochrane criteria).

Main Results:

  • Analyzed 29 studies on aminoglycoside ototoxicity, reporting hearing loss (0-57%), tinnitus (0-53%), and vertigo (0-79%).
  • Two studies on glycopeptide ototoxicity showed hearing loss frequencies of 54% and 55%.
  • Higher hearing loss rates were observed with gentamicin compared to other aminoglycosides; concomitant use of platinum agents, diuretics, and other medications increased risk.

Conclusions:

  • The incidence of aminoglycoside/glycopeptide-induced ototoxicity in children is highly variable.
  • Factors such as diagnosis, specific aminoglycoside, and co-administered medications significantly impact ototoxicity risk.
  • Age-dependent audiological examinations are recommended for children receiving these antibiotics, particularly when combined with other ototoxic drugs.
Abstract

More Related Videos

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

17.7K
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

19.4K

Related Concept Videos

Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
22
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
17
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
15
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
14
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
20
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
24